The influence of mild hypothermia on reversal of rocuronium-induced deep neuromuscular block with sugammadex
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hee Jong | - |
dc.contributor.author | Kim, Kyo Sang | - |
dc.contributor.author | Jeong, Ji Seon | - |
dc.contributor.author | Kim, Kyu Nam | - |
dc.contributor.author | Lee, Byeong Chan | - |
dc.date.accessioned | 2022-07-16T01:04:18Z | - |
dc.date.available | 2022-07-16T01:04:18Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2015-01 | - |
dc.identifier.issn | 1471-2253 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/158181 | - |
dc.description.abstract | Background: Mild hypothermia may be frequently induced due to cool environments in the operating room. The study analyzed patient recovery time and response to sugammadex after a prolonged rocuronium-induced deep neuromuscular block (NMB) during mild hypothermia. Methods: Sixty patients were randomly (1: 1) allocated to the mild hypothermia and normothermia groups, defined as having core temperatures between 34.5 -35 degrees C and 36.5-37 degrees C, respectively. Patients received 0.6 mg/kg of rocuronium, followed by 7-10 mu g/kg/min to maintain a deep NMB [post-tetanic count (PTC) 1-2]. After surgery, the deep NMB was reversed with sugammadex 4.0 mg/kg. The primary end-point was the time until the train-of-four (TOF) ratio was 0.9. Results: The appropriate neuromuscular function (TOF ratio >= 0.9) was restored after sugammadex was administered, even after hypothermia. The length of recovery in the hypothermia patients [mean (SD), 171.1 (62.1) seconds (s)] was significantly slower compared with the normothermia patients [124.9 (59.2) s] (p = 0.005). There were no adverse effects from sugammadex. Conclusions: Sugammadex safely and securely reversed deep rocuronium-induced NMB during mild hypothermia. An additional 46 s was required for recovery from a deep NMB in hypothermia patients. Based on the results, we think this prolonged recovery time is clinically acceptable. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.title | The influence of mild hypothermia on reversal of rocuronium-induced deep neuromuscular block with sugammadex | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Kyu Nam | - |
dc.identifier.doi | 10.1186/1471-2253-15-7 | - |
dc.identifier.scopusid | 2-s2.0-84986631556 | - |
dc.identifier.wosid | 000349792200003 | - |
dc.identifier.bibliographicCitation | BMC ANESTHESIOLOGY, v.15, pp.1 - 6 | - |
dc.relation.isPartOf | BMC ANESTHESIOLOGY | - |
dc.citation.title | BMC ANESTHESIOLOGY | - |
dc.citation.volume | 15 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 6 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Anesthesiology | - |
dc.relation.journalWebOfScienceCategory | Anesthesiology | - |
dc.subject.keywordPlus | TRAIN-OF-4 RATIO | - |
dc.subject.keywordPlus | SEVOFLURANE ANESTHESIA | - |
dc.subject.keywordPlus | VECURONIUM | - |
dc.subject.keywordPlus | NEOSTIGMINE | - |
dc.subject.keywordPlus | NORMOTHERMIA | - |
dc.subject.keywordPlus | RECOVERY | - |
dc.subject.keywordPlus | FLOW | - |
dc.subject.keywordAuthor | Hypothermia | - |
dc.subject.keywordAuthor | Neuromuscular blockade Rocuronium | - |
dc.subject.keywordAuthor | Sugammadex | - |
dc.identifier.url | https://bmcanesthesiol.biomedcentral.com/articles/10.1186/1471-2253-15-7 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.